{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276906","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.600488+00:00","generated_at":"2026-06-22T08:38:41.064248+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kura Oncology reports Phase 1b KOMET-001 data for ziftomenib in R/R AML; 600 mg shows 25% CR/CRh","bullets":["Phase 1b at 600 mg (N=12): 25% CR/CRh rate, 33% composite CR (75% MRD-), 42% ORR.","Phase 1a (N=30): 2 DLTs (pneumonitis at 400 mg, differentiation syndrome at 1000 mg); manageable safety.","Differentiation syndrome occurred in 7 Phase 1b patients; severity declined after DS Guidance implementation.","Oral presentation at ASH on Dec 10, 2022, will include preliminary data from 18 additional Phase 1b extension patients.","Ziftomenib is an oral menin-KMT2A inhibitor targeting NPM1m and KMT2Ar relapsed/refractory AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276906","json":"https://secwatch.observer/filing/0001193125-22-276906.json","markdown":"https://secwatch.observer/filing/0001193125-22-276906.md","text":"https://secwatch.observer/filing/0001193125-22-276906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312522276906/0001193125-22-276906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312522276906/d366823d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:38:41.064248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}